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Abstract 
Introduction 
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) with a peak 
onset between 15-30 years of age. The ethiology is unknown, but essential in the 
pathogenesis is an interplay between environment (microbiota), a dysfunctional 
immune system and a genetic predisposition.  
Treatment of IBD by corticosteroids, classical immunosuppressives and 
biological agents have potential side-effects and complications. Patients therefore 
often ask if alternative treatment can reduce or eliminate their disease or need for 
potent medication, and diet modifications has thus gained increasing interest as an 
alternative option. 
Food components may change the microbial composition in the gut, and 
thereby influence the immune response and inflammation in IBD. Both innate and 
adaptive immune responses in the gut are involved in IBD, and can be affected by 
changes in microbiota and diet intervention. 
Long chained polyunsaturated n-3 fatty acids (PUFAs) are essential 
components in marine oils and may exert anti-inflammatory effects in IBD through 
several mechanisms. They constitute substrates for production of anti-inflammatory 
lipid molecules – eicosanoids - change biochemical properties of cell membranes, or  
influence gene transcription; thus dampening inflammation. Atlantic salmon contains 
fish oil with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), as well as 
peptides and/or proteins with potentially biological effects. We tested how a regular 
high intake of Atlantic salmon influenced disease activity and inflammatory markers 
in patients with active UC. 
Further studies of marine nutritional products and a modified fatty acid was 
carried out in the dextrane sulfate sodium (DSS) chemically induced rat colitis model. 
This animal colitis model resembles human UC.   
Fish is a source of bioactive peptides that have demonstrated antihypertensive-, 
anti-oxidant-, as well as anti-proliferative properties. Accordingly, diets with fish 
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peptides, fish oil and a combination, were administered in the DSS colitis model to 
investigate potential anti-inflammatory effects.   
Krill oil is a novel source of n-3 marine fatty acids, with different chemical 
structure from fish oil, containing larger amounts of EPA and DHA bound to 
phospholipids. Krill oil also contains the natural anti-oxidant astaxanthin.  
  Tetradecylthioacetic acid (TTA) is a modified fatty acid containing sulphur in 
the 3-position, making it resistant against β-oxidation. It has demonstrated anti-
oxidant, lipid lowering as well as immunomodulatory effects in previous studies, and 
was therefore tested in our experimental colitis model to assess whether it could 
reduce colon inflammation and affect oxidative stress markers.  
Main objectives 
• Investigate the anti-inflammatory effects of a high intake of Atlantic salmon in 
patients with active UC 
• Assess the anti-inflammatory and anti-oxidative effects of fish oil, fish peptides 
and a combined diet in DSS induced colitis in rats 
• Assess the anti-inflammatory and anti-oxidative effects of krill oil in DSS 
induced colitis in rats 
• Investigate the anti-inflammatory and anti-oxidative effects of a modified fatty 
acid  - TTA -  in DSS induced colitis in rats 
Subjects and methods 
In the salmon diet pilot study (Paper I), all patients with active UC were recruited from 
the outpatient clinics, Stavanger University Hospital. Of the 23 patients included, six 
patients withdrew due to loss of motivation. Five more patients were excluded from 
further analyses because of fecal calprotectin < 50 mg/kg. Thus, twelve patients where 
available for analyses. After inclusion (visit 0), four weeks of wash out was followed 
by intake of 600 g Atlantic salmon weekly for eight weeks. At start (visit 1), and end 
of the diet intervention (visit 2), we rated the Simple Clinical Colitis Activity Index 
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(SCCAI), endoscopic score, histological score in rectum specimens, disease activity 
markers in plasma and feces, as well as fatty acid profile in plasma an rectum samples. 
We also calculated the anti-inflammatory fatty acid index (AIFAI). A food frequency 
questionnaire was filled out at inclusion (visit 0), and at the end of the study (visit 2).  
In the experimental animal studies (Papers II-IV) male Wistar rats were given 
intervention diets for four weeks, with chemical colitis induction the last week. Seven 
groups of 10 animals received the following diets:  
1) Standard diet (controls)  
2) Standard diet + DSS  
3) Fish oil (5%) + DSS  
4) Fish peptides (3.5%) + DSS  
5) Fish oil + fish peptides + DSS  
6) Krill oil (5%) + DSS  
7) TTA + DSS.  
Due to this design, the two control groups (standard diet and standard diet + DSS) 
were identical in the three studies reported in Papers II-IV. 
After four weeks, disease activity was rated according to the DAI. The animals 
were then anesthetized, sacrificed, and the major part of colon was removed. Colon 
length was measured, and tissue samples were isolated for rating of the histological 
combined score (HCS), measurements of selected cytokines, prostaglandins, mRNA 
expression, and markers of protein oxidative damage. The fatty acid profile was 
assessed in the krill oil, standard diet and standard diet + DSS groups.  
Results 
We found that: 
• High intake of salmon in patients with active UC reduced the SCCAI, increased 
the EPA and DHA levels and n-3/n-6 fatty acid ratio in plasma and rectum 
biopsies, as well as increased the AIFAI, although these observations were not 
supported by other analogue changes in disease activity markers. 
  
12 
  
• The fish peptides supplemented diet attenuated DSS induced colitis in rats as 
compared with fish oil according to an improved HCS, lower levels of 
KC/GRO; while fish oil increased the anti-inflammatory prostaglandin (PG)E3 
levels, especially when combined with fish peptides diet 
• Rats fed krill oil diet had retained their colon length versus rats treated with 
DSS alone, had lower levels of protein oxidative markers, increased EPA, -
DHA levels, -n-3/n-6 fatty acid ratio and AIFAI (and a pattern with consistently 
reduced TNF-α, KC/GRO and IL-1β levels at protein and mRNA levels, 
although not reaching statistical significant differences). 
• TTA fed rats had reduced protein levels of TNF-α, mRNA levels of IL-1β and 
IL-6 as well as lower levels of protein oxidative damage markers, and a reduced 
colon wall thickness compared with rats fed DSS, as assessed by 
transabdominal high frequency ultrasound. 
Conclusions 
We found that salmon fillets, as well as several marine nutritional products and a 
modified fatty acid may have beneficial effects in human UC and in an experimental 
animal colitis model resembling human UC. Although the biological effects are 
limited, fat fish fillets, fish peptides, krill oil and TTA should be further explored in 
controlled human IBD studies including patients in remission, and the effect in 
combination with medical therapy should be tested. Future human studies should take 
into account that genetic factors might explain some of the response variability in n-3 
interventions. High frequency ultrasound imaging may become a valuable non-
invasive tool in rat colitis models.  
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1.  Introduction 
1.1 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) comprises two main entities; ulcerative colitis 
(UC) and Crohn´s disease (CD). Both are chronic inflammatory diseases and show a 
remitting-relapsing course. UC is usually characterized by a diffuse and superficial 
inflammation of the colorectal mucosa, extending proximally to a variable degree 
(Figure 1). Bloody diarrhea frequently occurs during active flares of disease. Up to one 
quarter of the patients have a progressive disease course, do not respond to medical 
therapy, and will undergo a colectomy during their disease career (1).  
CD presents with a patchy transmural inflammation and may affect any part of 
the GI tract, from the oral cavity to the anus, but most frequently involves the 
ileocoecal region. In a majority of patients the deep inflammatory processes result in a 
course complicated by strictures, fistulas and abscesses (2). Surgical treatment is 
required in up to 80% after 20 years of disease (3). 
Figure 1. Ulcerative colitis  
 
Photo: T. Grimstad 
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1.2 Epidemiology 
The increasing incidence and prevalence of IBD in Northern Europe and North 
America during the last decades, most markedly for CD, appears to stabilize. In 
contrast, geographical areas in Europe with previously low incidences now reportedly 
show an increase of IBD. UC and CD presently affect up to 0.4% of the population in 
Europe, and are most frequently diagnosed in individuals between 15-30 years of age. 
Also, the incidence rates seem to follow a north-south gradient (4). Scandinavia, UK 
and North America are all regions with a high incidence of IBD, while Greece and 
Portugal represent countries with lower incidence rates. In Norway, the annual 
incidences for UC is about 16/100.000, and for CD 8/100.000 (5). 
1.3 Pathogenesis 
Growing evidence points to a dysregulated immune response against commensal gut 
microbiota in a genetically predisposed host as essential factors for the pathogenesis of 
IBD. In this setting, diet, surrounding microbiota and smoking have gained increased 
attention as important environmental elements in the pathogenesis (6).   
1.3.1 Basic principles of the immune system 
The main purpose of the immune system is to detect and destroy potentially invading 
pathogens and other danger molecules. The innate and adaptive immune system forms 
two different functional entities with close collaboration. Innate immunity serves as 
the first line of defence. It responds rapidly against evolutionary conserved specific 
molecular structures on pathogens, but has no memory for past events. Some epitopes 
of microorganisms have “pathogen-“ or “danger-associated molecular patterns” 
(PAMPS or DAMPS). Cell-surface located toll-like receptors (TLRs) and intracellular 
receptors like nucleotide oligomerization domain (NOD) are examples of important 
sensors for PAMPS and DAMPS. Physical and chemical barriers, secretory- and 
serum molecules, phagocytic cells (monocytes, macrophages and granulocytes) and 
dendritic cells are also components of the innate immune system.  
  
16 
  
 The adaptive immune system is much more specific although slower in its 
response. Lymphocytes, constituting T, B and natural killer (NK) cells originate from 
stem cells in the bone marrow and are distributed to their maturing organ: Thymus - T 
cells, and bone marrow – B cells. In the thymus, the T cells become immunologically 
educated and aquire ability to respond to specific antigens. The B cells develop 
antigen-specific receptors on their surface – B cell receptors.  
 Dendritic cells and macrophages present antigen to T cells which become 
activated and polarize into T helper subsets (Th1, Th 2, Th17) and T cytotoxic cells. 
 Th 1, Th 2 and Th 17 cells are essential upregulators of adaptive immunity. 
Their activation lead to secretion of local acting substances like cytokines and 
chemokines resulting in a cascade involving T cell differentiation and proliferation, 
and further cytokine release. T cytotoxic cells eliminate other cells infected by viruses 
or bacteria. In the early phases of the immune response, the specific nature of the 
antigen triggers sensing receptors and subsequent effector systems, resulting in an 
optimized immune reponse against the particular antigen.  
Some B and T cells furthermore mature into memory cells, being able to mount 
a rapid response when exposed to the same antigen a second time. This increases the 
immunological effect against a specific pathogen (aquired immunity) (7). 
Tolerance is the ability of the immune system to not respond to certain epitopes, 
such as “self”, thereby avoiding inappropriate activity under normal conditions. In the 
healthy subject there is a balance in the immune system between factors that dampen 
activity, such as regulatory T and B cells, interleukin (IL)-10, and stimulating factors, 
like the Th 17 cells and IL-17A, IL-17F and IL-22.   
Autoimmune diseases are classically characterized by a loss of tolerance against 
self antigens, resulting in autoreactive T cells, and B cell production of antibodies 
against autoantigens (8). Such autoreactive T and B cells may trigger chronic 
inflammatory processes.  
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1.3.2 Cytokines and chemokines 
Cytokines are small signal molecules, mostly produced by immune cells, allowing 
communication between cells. Cytokines stimulate or downregulate different cell 
types in the vicinity in an autocrine or paracrine way. The local cytokine profile 
created by innate immune cells like macrophages and dendritic cells determine how 
activated T-cells differentiate to specific subsets, and how these cell populations later 
proliferate. Cytokines act by activating designated receptors on the target cells, 
followed by intracellular signalling cascades controlling gene transcription and thus 
the cellular function (7). 
Cytokines may functionally be divided into pro-inflammatory, such as IL-1β, 
tumor necrosis factor (TNF)-α and IL-6, and anti-inflammatory, like IL-10 and 
transforming growth factor (TGF)-β. Different Th subsets tend to release different 
”cytokine profiles”, such as Th 1: IFN-γ, IL-2, IL-12; Th 2: IL-4, IL-13 and Th 17: IL-
17A, IL-17F and IL-22 (9). 
Chemokines are small signal molecules with effect on homing and migration of 
leukocytes. Chemokines guide leukocytes from the circulation to sites of 
inflammation. There are four groups, named C-, CC- CXC- and CX3C chemokines, 
according to the positions of their cysteine residues. Like cytokines, chemokines also 
act through designated receptors on target cells (10).  
1.3.3 The gut immune system in inflammatory bowel disease  
Under normal conditions, the immune response is tightly regulated, and inflammation 
downregulated once the invading pathogen is defeated. However, in chronic 
inflammatory conditions like IBD, the immune response is continuously upregulated. 
Organ-specific antibodies or autoreactive T cells do not seem to play a major role in 
IBD, but other dysregulations of mucosal and systemic immunity are clearly evident in 
both UC and CD. The integrity between the enteric flora and mucosal immune system 
appears disturbed, and a loss of tolerance towards the normal gut flora in IBD results 
in detrimental inflammatory activity (8). Dysfunctions in the innate immune system 
play pivotal roles in the pathogenesis of IBD. 
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 Several important components of innate immunity might be affected in IBD, 
such as secretory Ig A, defensins secreted from epithelial cells, the mucus layer, the 
epithelial layer with tight junctions between cells, and dysfunctions of lamina propria 
located macrophages, neutrophilic granulocytes, dendritic cells and NK cells. This 
leads to an aberrant influx of microorganisms or their degraded products into the 
lamina propria, and triggers an immunological response. B cells also play a role in the 
lamina propria in IBD, producing antimicrobial antibodies like IgA. 
Specific PAMPs or DAMPs on pathogens and other “danger-molecules” 
activate macrophages, dendritic cells and even epithelial cells through binding to 
innate sensors like TLR or NOD receptors. Dysfunctions in sensing and processing of 
signals may result in inappropriate activation of innate immune cells.  
When a foreign antigen is discovered by antigen-presenting cells, it is brought 
to an ”induction area”, a mesenteric lymph node or Peyer plaque by dendritic cells for 
presentation to naive antigen-specific T cells which then become activated and 
differentiate to specific Th cell subsets modulated by the surrounding cytokine profile. 
T cells then proliferate, and express chemokine surface receptors like CCR9 and 
enterotropic adhesion molecules like integrin α4β7 before being transported back to the 
“effector area” of the intestinal mucosa by efferent lymph vessels, the thoracic duct 
and blood. Effector T cells then secrete cytokines and chemokines that accelerate the 
inflammatory process. In addition, high levels of nitric oxide, oxygen radicals, 
eicosanoids and other effector molecules produced by macrophages contribute to the 
tissue damage in IBD (1, 2, 6). 
CD has been regarded a Th 1 mediated disease with elevated interferon (IFN)-γ, 
IL-12 and IL-18, while UC has been attributed to a modified Th 2 cytokine profile, 
with high levels of IL-4, IL-5 and IL-13 (6). TNF-α and IL-1β are essential pro-
inflammatory cytokines that are increased in the intestinal mucosa in IBD (2). In 
addition, Th-17 produced IL-17, and IL-23 generated by macrophages and dendritic 
cells influence pathways important for inflammation in both UC and CD (2, 11). 
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1.3.4 Inflammatory markers: CRP and fecal calprotectin 
C-reactive protein (CRP) produced in hepatocytes is an essential marker of the acute 
phase reaction in humans. To some degree serum levels of CRP reflect the degree of 
IBD disease activity (12), but to a lesser extent in UC than in CD (13).  
Calprotectin is a cytosolic calcium- and zinc binding protein produced and released 
from macrophages and neutrophils. Fecal calprotectin levels appear to reflect the 
amount of neutrophil infiltration in the intestinal wall (13). Thus, measurements of 
fecal calprotectin permit differentiation between IBD and irritable bowel syndrome 
(IBS) with high accuracy. Fecal calprotectin can also separate active from inactive 
IBD, and is superior to CRP in assessing intestinal inflammation (14).  
1.4 Genetics in IBD 
Genes are made up of densely packed double stranded DNA in 23 pairs of 
chromosomes located in the cell nuclei. The DNA sequences code for and determines 
the structure and function of proteins and peptides. Through activation by transcription 
factors, genes are transcribed to messenger RNA (mRNA). The sequence of bases in 
the mRNA molecule is then read in order to create a sequence of aminoacids, 
ultimately forming a protein of specific length, structure and folding. Gene expression 
is regulated by RNA-DNA interactions, by microRNA molecules or other epigenetic 
changes, such as methylation or acetylation of the DNA-histone complexes. Also, the 
synthesized peptide or protein can be modified by post-translational changes, such as 
adding a functional group or a protein, or making a structural or chemical change (15). 
Transcription factors are key regulators of gene transcription. They contain DNA-
binding domains which allow binding to a defined DNA sequence, frequently in the 
regulatory region of a specific gene. These factors also contain regions that interact 
with RNA polymerase, necessary for transcription (16).  
Genome-wide assossiation studies (GWAS) permit the whole human DNA 
sequence to be searched for susceptibility genes for different diseases, including genes 
for IBD. In a recent study 163 IBD loci were discovered. Of them, 110 were shared by 
both UC and CD, and 23 were associated with UC only (17). Although the disease 
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heredity explained by known IBD loci was reported to only 23% in CD (18) and 16% 
in UC (19), valuable information about key genes involved and pathogenetical 
pathways has been revealed from such studies. It is, however, important to know that 
only a minor fraction of IBD susceptibility can be explained by these candidate genes, 
and that they represent variants of normal genes, and not monogenetic disease. 
1.5  Oxidative stress - reactive oxygen species - antioxidants 
Reactive oxygen species (ROS) have important physiolocical functions in cell 
signalling and defence against foreign microorganisms. They are highly reactive 
substances formed during both normal and abnormal conditions. ROS are produced 
and released into phagocytic blebs of macrophages and neutrophils when they 
recognize, phagocytize and destroy pathogens (20, 21).  
An example of ROS is the superoxide anion radical, O2
- 
!. It has an extra 
electron, and is continuously produced as a by-product of the respiratory chain energy 
producing process. Hydrogen peroxide, H2O2 , hypochlorous acid, HOCl , the 
hydroxyl radical, OH!,  nitric oxide, NO, and peroxynitrite, ONOO
-
  are other 
examples of reactive molecules (20). ROS are extremely reactive molecules and may 
damage normal cellular components and cellular life if not opposed by strong 
protective anti-oxidant mechanisms of both enzymatic and non-enzymatic nature (22).   
In chronic inflammatory conditions like IBD there is a relative excess of ROS.    
This “oxidative stress” can lead to tissue damage through oxidative chain reactions 
with production of toxic lipid peroxides, protein carbonyls or DNA base 
hydroxylations (22).  
1.6 Treatment 
The standard medical treatment of IBD the last decades has been 5-aminosalisylates, 
corticosteroids and immunosuppressive drugs (azathioprine and methotrexate), 
inducing clinical response or remission in a substantial proportion of patients. The 
introduction of biological treatment such as TNF-α-inhibitors and anti-integrins 
provides a more specific immune therapy with additional increase in the mucosal 
healing rate. However, these regimens also increase the risk of infections and rare 
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complications and side effects (23). Alternative and non-medical therapy, such as 
dietary intervention, is therefore often asked for by IBD patients.  
1.7 Diet and IBD 
Dietary habits in the Western world have changed considerably the last century, 
whereas our genes are unchanged. At the same time, human physical activity level has 
decreased. New life style related diseases have emerged, such as essential 
hypertension and diabetes. This has partly been attributed to a change in the fatty acid 
intake (24).  
 Food has gained increased attention as a pathogenetic factor in IBD. Recent 
research has highlighted the influence of dietary factors on immune functions (25), as 
well as the interplay between diet, microbiota and the immune system (26, 27). 
Dietary components can alter the composition of the intestinal microbial flora, which 
may lead to beneficial changes in both innate and adaptive immune responses (26).  
1.7.1 Polyunsaturated fatty acids (PUFAs) 
Fatty acids serve important biological functions in the human body, and are crucial 
components in the phospholipid bi-layer of cell membranes. Fatty acids consist of a 
carbon chain with a methyl group at one end and a carboxyl group at the other one. A 
saturated fatty acid does not have double bonds in the carbon chain, while unsaturated 
fatty acids have one (monounsaturated) or more (polyunsaturated) C=C bonds. The 
nomenclature of fatty acids, such as ”C20:5n-3” describes the number of carbons in 
the chain followed by the number of double bonds, and finally the ”omega-” or ”n- ”, 
indicating the number of carbons from the methyl end to the first double bond. Of 
polyunsaturated fatty acids (PUFAs), the n-3 and n-6 PUFAs are the most important 
groups (28). 
   Fatty acids are esterified to glycerol molecules to form mono-, di-, or 
triglycerides, containing one, two or three fatty acids, respectively. Fatty acids may 
also be divided into essential and non-essential fatty acids. The basic essential fatty 
acids are linoleic acid (LA), “C18:2n-6” and alpha-linolenic acid (ALA), “C18:3n-3” 
(Figure 2). These must be supplied in the diet, and serve as substrates for the 
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production of other long chain PUFAs. Through metabolism by elongase and 
desaturase enzymes, the human body can synthesize important fatty acids like 
“C20:4n-6” arachidonic acid (AA) from LA and “C20:5n-3” eicosapentaenoic acid 
(EPA) from ALA. However, the n-3 conversion to EPA is limited to 8-20% of the 
existing ALA (29). Therefore, PUFAs like EPA, and its elonged products, “C22:5n-3”, 
docosapentaenoic acid (DPA) and “C22:6n-3” docosahexaenoic acid (DHA) are better 
supplied by diet than by endogenous production. 
The n-3 PUFAs have several beneficial biological effects in humans: EPA and 
DHA are antithrombotic, lower triglycerides, reduce cardiac mortality, reduce blood 
pressure, reduce joint pain in rheumatoid arthritis, and may beneficially influence 
inflammatory diseases (30). In contrast, an increased n-6/n-3 ratio in the diet has been 
associated with higher rates of inflammatory and autoimmune diseases (24).  
 
Figure 2. Essential fatty acids.  
 
 
 
 
 
 
Reprinted from “ALA” and “LA” in Wikipedia. Retrieved on November 30, 2012 
from http://en.wikipedia.org/wiki/File:ALAnumbering.png and 
http://en.wikipedia.org/wiki/File:LAnumbering.png 
 
LA – linoleic acid 
ALA – alpha -linoleic acid 
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Eicosanoids 
Eicosanoids are oxidised, short-lived mediators of inflammation derived from 20 
carbon polyunsaturated fatty acids (31). The n-6 PUFA AA is abundant in cell 
membrane phospholipids of immune cells like macrophages and neutrophils. It is a 
major substrate for production of the generally pro-inflammatory eicosanoids. AA may 
be metabolized through 5-lipoxygenase (LOX), resulting in leukotriene (LT) 4-series 
of A, B, C, D and E, or through cyclooxygenase (COX) 1 and -2 pathways, producing 
prostaglandin (PG) D, E, F and I, as well as thromboxanes (TX), of the 2-series (32) 
(Figure 3). 
A competitive substrate is the n-3 PUFA EPA which gives rise to anti-
inflammatory substances. When dietary EPA replaces AA, the same enzyme systems 
produce leukotrienes (LOX) of the 5 series and prostaglandins (and thromboxanes) 
(COX) of the 3 series believed to have less inflammatory potential (32).  
Other eicosanoids have emerged in recent years with anti-inflammatory 
properties, like resolvin E1 derived from EPA and resolvin D1-D6 from DHA. In 
addition, AA may give rise to anti-inflammatory lipid mediators in form of lipoxins, 
like lipoxin A4 (33). 
1.7.2 Fish oil 
Fish oil contains the important marine PUFAs EPA, DHA and DPA. The most 
important sources of marine n-3 fatty acids are fat fish such as salmon, trout and 
mackerel. EPA and DHA typically constitute about 18 % of total fat (34), which 
provides about 2g fatty acids in 100g fat fish fillet (30). Dietary fish oil may be 
supplied as fish oil concentrates in capsulas or as fish fillets. A more novel contributor 
to dietary marine PUFAs is krill, a crustacean living in the arctic seas. Krill provides 
n-3 with a large fraction bound to phospholipids instead of triglycerides, as well as a 
natural antioxidant, astaxanthin (34).  
The anti-inflammatory effect by marine PUFAs may be attributed to several 
mechanisms, including transcription factor modulation, altered substrate for 
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production of eicosanoids (EPA for AA) and modifications of plasma membrane 
organization (“lipid rafts”) (35). 
 
Figure 3. Outline of eicosanoid synthesis from arachidonic acid. Selected products 
from eicosapentaenoic acid are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: COX, cyclooxygenase; LOX, lipoxygenase; PG, prostaglandin; TX, 
thromboxane; LT, leukotriene.  
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The anti-inflammatory fatty acid index is the sum of EPA, DHA, dihomo-gamma-
linolenic acid (DGLA) “C20:3n-6” divided by AA x 100. An increased AIFAI has 
been associated with a decrease in PGE2 (36). 
1.7.3 A modified fatty acid  
Tetradecylthioacetic acid (TTA) is a modified, syntetic fatty acid with a sulphur atom 
in the 3-position from the carboxyl end, making the molecule resistant to beta-
oxidation (37). It is a pan-peroxisome proliferator-activated receptor (PPAR) agonist 
and has demonstrated immunomodulatory properties in reducing IL-2 levels and 
increasing IL-10 (38), as well as having an anti-oxidant potential. The effects from 
TTA resembles a potent n-3 fatty acid in reducing lipid peroxidation and oxidative 
stress (39, 40) and in lowering serum triglycerides (41). 
1.7.4 Bioactive peptides  
Peptides are protein fragments with less than 50 aminoacids. Bioactive peptides have 
potentially beneficial biological effects when supplied in the diet. They are often 
encrypted in larger proteins and are released after cleavage by proteolytic enzymes 
following intestinal digestion (42). These substances may have a variety of biological 
functions, dependent on their size and structure. Characteristic for the biologically 
active peptides, is that they contain mostly 2-9, potentially up to 20 amino acids, with 
a molecular weight of < 10,000 Dalton, preferably < 1,000 Dalton (43). Such peptides 
may be absorbed unchanged or with only small modifications of structure. They can 
also act directly in the gastrointestinal tract or via receptor mediated signalling (42). 
They may enrich the diet, providing ”nutraceuticals”, with potentially increasing effect 
with higher amount in the diet.  
Bioactive proteins and peptides in milk, such as lactoferrin, has been the focus 
for considerable research. Other sources for bioactive peptides are soy beans, meat and 
fish (42, 43). 
 
 
  
26 
  
1.7.5 Fish peptides 
Hydrolysates containing fish peptides from fish carcasses are produced by adding 
water after mincing and then conducting proteolytic cleavage by adding proteases 
(44). Fish peptides exist as commercially available products. One specific dietary fish-
derived hydrolysate contained large amounts of protein constituents, 75-80%, in forms 
of peptides or amino acids. Smaller studies using this fish peptide product have 
reported reparative properties in cell cultures from NSAID induced damage (44), and 
small intestine protective potential in rodents and humans when administered together 
with NSAID (45, 46). Fish peptides may have beneficial effects in IBD patients (47). 
1.8 Animal models of IBD 
There is a number of animal models of IBD used to investigate disease mechanisms, 
and to evaluate novel treatment interventions in IBD. The main types are spontaneous 
colitis models, inducible colitis models, genetically modified models and adoptive 
transfer models (48). The ideal IBD animal model should present disease features 
identical to human IBD: It should have the same ethiology (be induced by the same 
pathogenetic factors), involve identical pathophysiological patterns, and present the 
same clinical, histological and immunological characteristics. In addition, it should 
respond to the same treatments as the human disease (49).  
Main advantages of animal models are that trials can be conducted in very 
controllable environmental conditions, on genetically identical animals, and the trial 
logistics are simpler than in human experiments. Although animal models do not fully 
reflect the human disease, they have provided important insight regarding complex 
pathogenetic mechanisms in IBD, including Th function (Th 1, Th 2, Th 17), 
regulatory cell functions, TLRs and bacteria/epithelium interactions (50).   
1.9 Specific theoretical considerations regarding some aspects of the projects 
In this project, several advanced mechanisms and concepts are involved. In the 
following section a closer description of the theoretical background is given. 
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1.9.1 Transcription factors as regulators of inflammation 
Nuclear factor kappa B (NFκB) 
NFκB transcription factors comprise a family of dimeric proteins present in 
cytoplasma of mammalian cells. Most NFκB molecules include the p65 (Rel A) 
subunit. Under unstimulated conditions, they are bound to inhibitory proteins called 
inhibitory (I)κB and are inactive. In classic activation of NFκB, activation of TLRs 
triggers a signalling cascade which results in proteolytic degradation of the IκB. This 
allows NFκB to translocate to the nucleus where it binds to DNA promoter regions, 
and regulate transcription of a variety of “inflammatory” genes such as genes encoding 
IL-1, TNF-α, IL-6, and IL-23, chemokines, cell adhesion molecules, inducible NO 
synthase (iNOS), COX-2, as well as anti-apoptotic genes and cell cycle genes (20, 51) 
(Figure 4). TNF-α may potentiate NFκB activation through positive feedback (51). 
Levels of NFκB p65 are elevated in nuclear extracts from mucosa in both CD and UC 
patients as compared with healthy subjects (52).  
 
 
 
 
 
 
 
 
 
 
  
28 
  
 
Figure 4. NFκB mechanism of action.  
  
 
Reprinted from “NFκB”, in Wikipedia, retrieved November 30, 2012 from 
http://en.wikipedia.org/wiki/File:NFKB_mechanism_of_action.png 
 
Peroxisome proliferator-activated receptor γ (PPAR-γ) 
PPARs are proteins that are part of the nuclear receptor family, and consist of three 
subtypes: PPAR-α, PPAR-β/δ and PPAR-γ. PPAR-γ is expressed in epithelial cells, in 
macrophages and lymphocytes in the colon (53), and reportedly plays a role in 
intestinal inflammation (54). PPAR-γ is located in the cell nucleus, and is activated by 
natural or synthetic ligands. It then forms a heterodimer with the retinoid X receptor 
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before binding to the peroxisome proliferator response elements gene promoter, and 
regulates the expression of pro-inflammatory mediators (55). The PPAR-γ coactivator 
1 (PPARGC-1α) aquires transcriptional activity after binding (“docking”) to PPAR-γ, 
and may then regulate genes related to energy metabolism (56).   
When activated, PPAR-γ downregulate the inflammatory response, interferes 
with inflammatory signal pathways such as the transcription factor NFκB system, and 
reduces the production of proinflammatory mediators like cytokines, chemokines and 
adhesion molecules, as well as proliferation factors of inflammatory cells (53, 57). 
Likewise, PPAR-α, with a high expression in sites like the vascular walls and 
the liver, also seems to play a role in the inflammatory response through antagonizing 
NFκB (58).  
In IBD both nuclear factor kappa B (NFκB) and peroxisome proliferator-
activated receptor γ (PPAR-γ) play important roles in the regulation of the 
pathophysiological processes (6, 53).    
1.9.2 Sirtuins 
Sirtuins (SIRT), are proteins that modulate pathways related to stress response and 
metabolism, and are also considered to be cellular redox sensors. In mammals there 
are seven sirtuins, SIRT 1-7.  SIRT1 is a 100 kDa protein located in the cell nucleus 
and provides prolonged lifespan in model organisms. SIRT1 may act as an inhibitor of 
NFκB activity, and decreased levels of SIRT1 gene expression were associated with 
increased NFκB activation and colitis in mice (59). 
SIRT4 is a smaller, mitochondrial protein involved in energy production during 
stress and nutrient adaptation. The sirtuins have two characteristic enzymatic features: 
1) Protein deacetylase activity, which is Nicotinamide adenine dinucleotide NAD
+ 
dependent, and 2) ADP-ribosyltransferase activity. They target certain acetylated 
proteins substrates (59, 60).   
1.9.3 Protein markers of oxidative stress - Advanced glycation end products 
Excessive ROS activity leads to oxidation of proteins. Protein carbonyl derivates are 
generated by oxidative cleavage, through introduction of a double carbon bonding to 
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oxygen, C=O, into proteins, by lipidperoxidation and formation of malondialdehyde 
(MDA). They are advantageous in the laboratory as oxidative biomarkers due to their 
relative stability. Glutamic and aminoadipic semialdehydes (GSA and AASA) are 
generated after direct oxidation of amino acid side chains in arginyl or prolyl residues 
(GSA) or lysyl residue (AASA) (61).  
A particular branch of protein carbonyls are advanced glycation end (AGE) 
products. Sugars may react with protein amino groups non-enzymatically to form so 
called Sciff bases, thereafter early glycation products (Amadori products). Through 
several modifying reactions they generate AGE products (62). Carboxymethyl-lysine 
(CML) is a marker of both glycoxidation and lipoxidation while carboxyethyl-lysine 
(CEL) is a glycoxidation product (62). 
In UC, increasing urinary levels of pentosidine, an AGE product, correlates 
with disease activity (63).  
AGE products have been linked to inflammatory mechanisms as the interaction 
with their receptor, RAGE, may induce activation of NFκB, and consequently increase 
expression of pro-inflammatory mediators (64). 
1.9.4 KC/GRO – CXCL1 
The chemokine CXCL1, also called Growth-regulated oncogene (GRO)-α in humans, 
is expressed by macrophages, neutrophils and epithelial cells. It binds to the receptor 
CXCR2 and attracts neutrophilic granulocytes (65). Both CXCL1 and CXCR2 were 
upregulated in active IBD patients (66). In rodents, Keratinocyte chemoattractant (KC) 
is regarded homologous to human GRO-α/CXCL1 (67).   
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2. Aims of the study 
 
• Investigate the influence of a regular high intake of Atlantic salmon fillets on 
disease activity, inflammatory markers and fatty acid profile in blood and colon 
samples in patients with active UC. 
• Investigate the anti-inflammatory and anti-oxidant effects of dietary fish 
peptides as compared with (a) fish oil and (b) a combined fish oil − fish 
peptides diet in a DSS induced rat colitis model.   
• Evaluate the anti-inflammatory and anti-oxidant effects of dietary krill oil in 
DSS induced colitis in rats as compared with control rats that were both 
exposed and not exposed to DSS. 
• Evaluate the anti-inflammatory and anti-oxidant effects of tetradecylthioacetic 
acid in DSS induced colitis in Wistar rats as compared with control rats that 
were both exposed and not exposed to DSS. 
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3.  Subjects/animals and methods 
3.1 Ulcerative colitis study (Paper I) 
Subjects 
Twenty-three patients were included in the study, of which six patients withdrew due 
to loss of motivation to follow the prescribed diet. Five more patients were excluded 
due to fecal calprotectin levels < 50 mg/kg.  
 After four weeks wash out with dietary restrictions to minimize biological n-3 
effects from the background diet, eight weeks of salmon intake of 200 grams three 
times weekly followed.    
Study diet 
The Atlantic salmon used in the study was produced at EWOS innovation AS, Dirdal, 
Norway. The salmon feed contained vegetabile oils and marine oils in a 1:1 ratio. 
Salmon fillet dinner portions were cooked and vacuum packed at the canteen at 
Haukeland University Hospital, ready for distribution to study participants.  
Fatty acid analysis of total lipids in plasma and colon 
We used a direct methylation method, and the same method for both plasma and colon 
FA analyses, modified from Shirai (68).  
First, 20 µl of plasma or tissue from four rectal biopsies (weighing 2-9 mg) 
were added into a vial. Then 0.4 ml 2% H2SO4 in methanol (v/v) (derivatization 
solution) and 0.4 ml toluene containing 5 µg C21:0 (internal standard solution) were 
added. The samples were heated for 1 hr at 90
o
C (69), cooled to room temperature and 
0.3 ml water was added into the samples. Also 120 µl 1.5 M K2CO3 in water 
(neutralization solution) was added. After centrifuging, about 200 µl of the toluene 
upper layer containing fatty acid methyl esters was transferred into autosampler vials 
and stored at -20
0
C before analyzed by gas-liquid chromatography. 
 
Gas chromography of fatty acids 
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Gas chromatography was performed with GC 8000 TOP (Finnigan, USA), equipped 
with a programmable temperature vaporization injector (PTV), flame-ionization 
detector (FID), AS 800 autosampler and with a fused silica capillary column coated 
with dimethylpolysiloxane stationary phase, DB1-ms (60m x 0.25mm x 0.25um) (J &  
Scientific, USA).  
Identification of fatty acids 
The GC signal was acquired and evaluated with Chromeleon software (Dionex, ver. 
6.80, USA). The baselines of chromatograms of each sample were corrected and 
adjusted in order to identify and quantify the fatty acids. Peaks were identified by 
means of known fatty acid standards. Detailed identification by means of mass spectra, 
obtained by GC/MS analysis (GCQ, Finnigan, USA) on the same column was carried 
out before the study.  
Diet questionnaire 
A validated FFQ semi-quantitative questionnaire designed to capture dietary habits 
and intake of dietary supplements during the last year was filled in at the start and at 
the end of the study (70). It includes questions about intake of 255 food items, 
including 10 questions regarding cold cuts and spreads made of fish/shellfish, 16 
questions about fish/shellfish eaten for dinner, and four questions regarding cod liver 
oil/cod liver oil capsules/fish oil capsules.   
Disease activity 
Simple Clinical Disease Activity Index 
The SCCAI is developed to evaluate disease activity in patients with UC (71). It is 
based on symptoms and signs and contains six items: stool frequency at day and night-
time, urgency before defecation, the amount of blood in the stools, general well-being, 
and presence of extra-intestinal manifestations such as: arthritis, pyoderma 
gangrenosum, erythema nodosum and uveitis. Each item is given a score. Maximum 
total score sum is 19, and a score of ≥ 4 indicates active colitis (Figure 5). 
  
34
  
 
                Figure 5. The SCCAI. 
 
 
Endoscopical examination 
Following bowel cleansing with a rectal enema (Klyx
®
) a limited simoidoscopy was 
performed and the grade of macroscopical inflammation rated according to a scale 
from 0-3: Grade 0 - normal mucosa (no inflammation); Grade 1 – mucosal oedema 
and altered vascular pattern (mild inflammation); Grade 2 – mucosal oedema, no 
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visible vascular pattern, presence of erosions (moderate inflammation); Grade 3 – 
ulcerations and spontaneous mucosal bleeding (severe inflammation) (72).    
Histological investigations   
During the sigmoidoscopy procedure, six biopsies were taken approximately 8 cm 
from the anus, at the point of most visible inflammation. Four biopsies were cooled on 
ice before swiftly transferred to -70° C for later FA analyses. The remaining two 
biopsies were placed in formaline, embedded in paraffin and Hematoxylin-Eosine (H-
E) stained before a section from both biopsies were evaluated by a senior pathologist 
unaware of the protocol. The degree of inflammation was then rated as follows: Grade 
0 - normal mucosa; Grade 1A – chronic lamina propria inflammatory infiltration with 
no effect on the mucosal lining or crypts, and no or mild architectural disorder; Grade 
1B - chronic inflammatory infiltration of the lamina propria not excluding the mucosal 
lining with no or mild architectural disorder; Grade 2 - mild crypt injury with acute 
inflammatory cell infiltration; Grade 3 - extensive crypt injury with crypt abscesses 
and ulcerations. 
Grade 0 reflects clinically inactive disease, grade 1 mild disease, grade 2 
moderate disease and grade 3 indicates severe disease (72). 
Inflammatory markers 
An immunoassay based 21-plex kit from LINCO® (Millipore Corporation, Billerica, 
MA 01821, USA) was used on a Bio-plex 200 suspension array system from Bio-
Rad® (Bio-Rad Life Science Research Group, Hercules, CA 94547, USA) to measure 
plasma cytokines. Further processing was performed by a Bio-plex manager 4.1 
software supplied from Bio-Rad®. The 21-plex kit included IL-1β, IL-2, IL-6, IL-10 
and TNF-α.  
High-sensitivity CRP was analysed at the Stavanger University Hospital´s 
routine laboratory. Plasma levels of homocysteine and malondialdehyde (MDA) were 
analysed as markers of oxidative damage. Levels of fecal calprotectin were analysed 
by the PhiCal Test® (NovaTec Immunodiagnostica GmbH, Dietzenbach, Germany), 
an ELISA based method. 
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Routine laboratory tests  
After an overnight fast, haemoglobin, leukocytes, platelets, creatinine, alanine 
aminotransferase (ALAT), alkaline phosphatase (ALP), albumin, and electrolytes were 
analysed at the Stavanger University Hospital´s routine laboratory.   
3.2 Animal studies (Papers II-IV)  
Animals 
The animal experiments were carried out at Vivariet, Haukeland University Hospital, 
Bergen. Male Wistar rats, 12 weeks old (Mollegaard and Blomholtgaard, Denmark) 
with a mean weight of approximately 360 g at arrival, were housed in Makrolon III 
cages in an open system, with five animals in each cage. They were kept under 
standard laboratory conditions with temperature 22 ± 1 °C, dark/light cycles of 12/12 
h, relative humidity 55 ± 5 % and 20 air changes per hour and had free access to food 
and water.  
Dietary intervention 
The animals were divided into groups of 10, and after seven days of acclimatization, 
they started a dietary intervention which lasted for four weeks. To develop colitis, the 
animals were exposed to DSS the last week.  
Three different studies were scheduled, in which animals received diets 
containing fish oil (5%), fish peptides (3.5%) or combined fish oil + fish peptides 
(Paper II), krill oil (5%) (Paper III), or TTA (0.4%) (Paper IV) respectively. All 
animals had free access to the feed on day 1-29. To minimize the total number of 
animals, the three experiments with identical methodology and conditions were 
performed simultaneously, and the control groups 1 (standard diet) and 2 (standard 
diet + DSS) were identical (Figure 6). 
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Figur 6. Design of dietary rat experiment. 
 
 
 
 
 
 
 
The diets contained (w/w) 5% lard (except the fish oil diets) (generous gift of 
Ten Kate Vetten BV, Musselkanaal, Netherlands), soy oil (2%) (Dyets Inc., 
Bethlehem, PA, USA), and 20% casein (except the fish peptides diets) (Sigma-
Aldrich, St. Louis, MO, USA). The other constituents of the diets were cornstarch, 
dyetrose, sucrose, fiber, AIN-93G mineral mix, AIN-93 vitamin mix, L-Cysteine, 
Choline bitartrate (Dyets Inc.), and tert-butyl-hydroquinone (Sigma- Aldrich). 
The prescribed diets are shown in Table 1. 
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Table 1.  Intervention diets in animal studies (Papers II-IV), (g/kg). 
    
 Ingredients Control FO FP FO + FP      KO      TTA 
KO     50  
FO  50  50   
FP   35 35   
TTA      4 
Lard 50  50  50 50 
Soy oil   20 20 20 20 19 20 
Casein 200 200 165 165 190 200 
Cornstarch 397 397 397 397 378 397 
Dyetrose 132 133 132 132 126 132 
Sucrose 100 100 100 100 95 100 
Fiber 50 50 50 50 48 50 
AIN-93G mineral mix 35 35 35 35 33 35 
AIN-93 vitamin mix 10 10 10 10 10 10 
L-Cysteine 3 3 3 3 3 3 
Choline bitartrate 2.5 2.5 2.5 2.5 2.4 2.5 
tert-Butyl-hydroquinone 0.014 0.014 0.014 0.014 0.013 0.014 
 
 
Colitis induction 
The DSS colitis model 
Dextran sulfate sodium is a synthetic polysaccharide which provides a chemically 
induced colitis in rodents when administered in drinking water. The DSS colitis model 
used in rodents was originally described in hamsters in 1985 (73), later in mice (74) 
and in rats (75) as an experimental colitis reminiscent of UC. Studies regarding both 
acute colitis (4-9 days of DSS exposure 2-5%) and chronic colitis (continuous or 
several cycles of 5-7 days of DSS exposure) have been conducted (48). DSS induced 
inflammation only affects the colon and has clinical as well as morphological 
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resemblance to UC (75). The colitis results from a toxic effect from DSS on epithelial 
cells, leading to barrier defects and increased mucosal permeability. This allows the 
passage of DSS molecules and, most importantly, the entrance of luminal 
microorganisms and antigens into the mucosa provoking a vigorous inflammatory 
response (48). Acute rodent DSS colitis is located to the mucosa and lamina propria 
and is characterized by mucosal erosions, epithelial regeneration and partly cryptitis, 
typically mostly defined to the left colon (74, 75).  
In our experiment, all animals except for controls had 50 g/L of DSS (MW 44 
000, TdB Consultancy AB, Uppsala, Sweden) added to the drinking water for 7 days 
(days 23-29) in order to induce an acute colitis resembling human UC (Figure 6).  
Descriptives 
The animal weight, feed intake and the DSS consumption were recorded before and 
during the DSS exposure, from days 23-29. Two animals died during the DSS week, 
both had severe colitis. 
Animal sacrifice 
All the rats were killed on day 30 of the experiment. In an anesthesia chamber, the 
animals were anesthetized with 2 % Isoflurane (Forane, from Abbot Laboratories Ltd, 
Illinois, USA). Then thoracotomy, cardiac puncture, and exsanguination were 
performed. 
Disease activity evaluation 
Disease Activity Index 
DAI is an instrument for assessment of  “clinical” disease activity (76) and is based on 
weightloss, stool concistency and rectal bleeding. Each item is rated from 0-4, and the 
sum is divided by 3 (77). All rats were placed in individual cages the last day of DSS 
intake, and DAI (Table 2) assessed after 24 hours. 
 
 
  
40 
  
Table 2.  Disease Activity Index (DAI) scoring 
    
DAI score* Weight loss (%) Stool concistency Rectal bleeding 
 
0 
 
0 
 
Normal 
 
Normal 
1 1-5   
2 5-10 Loose stools  
3 10-20   
4 >20 Diarrhea Gross bleeding 
 
*From (77) 
 
Colon length (Papers II-III) 
Shortly after animal sacrifice, the colon segment was removed from the colocecal 
junction to the anal verge, rinsed with phosphate-buffered saline and the length of the 
unstreched colon was measured. 
Histopathological examination 
Following length measurement, colon samples from the proximal and distal ends and 
the middle part were separated, divided longitudinally and placed in 10% 
paraformaldehyde. After being embedded in paraffin, sections were stained with H–E. 
One section from each location of the colon was evaluated using an Olympus BX 51 
microscope at magnification x 400 by a senior pathologist unaware of the study 
protocol.  
            A crypt and inflammatory score were determined for each section. The crypt 
injury was graded as follows: grade 0, intact crypts; grade 1, loss of the bottom third of 
crypts; grade 2, loss of the bottom two-thirds of crypts; grade 3, loss of the entire crypt 
with the surface epithelium remaining intact; grade 4, loss of the entire crypt and 
surface epithelium. Likewise, the severity of inflammation was also graded: grade 0, 
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normal; grade 1, focal inflammatory cell infiltration; grade 2, inflammatory cell 
infiltration, gland dropout, and crypt abscess; and grade 3, mucosal ulcers. 
Both scores include a measure of involvement: grade 1, 1% to 25%; grade 2, 26% to 
50%; grade 3, 51% to 75%; grade 4, 76% to 100%. Finally, the histological combined 
score (HCS) was calculated as the sum of the crypt and inflammatory scores, and was 
assessed in all three selected locations of the rat colons (78). 
Cytokine analyses in rat colon 
Preparations 
A 50-mg full wall colon sample cut into minute pieces was placed in cooled lysis 
buffer consisting of 10 ml premade Tris Lysis Buffer (20 mM Tris, pH 7.5, 150 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, and 1% Triton-X-100) (Meso Scale Discovery, 
Gaithersburg, MD, USA) with 1% bovine serum albumin (Meso Scale Discovery), one 
Complete Mini, EDTA-free protease inhibitor cocktail tablet (Roche Diagnostics 
GmbH, Mannheim, Germany), 100-ml phosphatase inhibitors I and II (Sigma, Saint 
Louis, Missouri, USA), 100 ml 1 M NaF, and 100 ml Non-Idet P40 (Roche 
Diagnostics) protected from daylight, and air was finally added to complete the lysis 
buffer. After placing the sample in the cooled lysis buffer, a VDI 12 homogenizator 
disruption probe with dispersion tool S12N-5 S (VWR international, West Chester, 
Pennsylvania, USA) was applied for 15–90 s and repeated once if the sample was 
considered not fully homogenized. The homogenisate was then centrifuged for 10 min 
at 14,000 rpm (4°C) using a Kubota 2800 with an RS-240 rotor (Kubota, Tokyo, 
Japan). This step was repeated with the supernatant only. The final supernatant was 
collected and stored at -70°C until further analysis. 
Tissue cytokine analyses 
Custom-made rat cytokine 4-plex kits including IL-1β, IL-5, interferon (IFN)-γ, and 
chemokine (C-X-C motif) ligand 1 (CXCL1 also known as KC/GRO), and single-plex 
kits with TNF-α (Meso Scale Discovery, Gaithersburg, MD, USA), were used to 
measure cytokines in the supernatant from the homogenisate. The analyses were 
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performed according to the manufacturer’s recommendations. The assays from MSD 
(Meso Scale Discovery) are immunoassays based on electrochemiluminiscence for 
detection. This provides a large detection range, high sensitivity and a low rate of 
interference from other compounds. 
Cytokine levels were reported as µg/kg (wet weight) in Paper II, as 
concentration pg/ml in Paper III and as µg/g (wet weight) in Paper IV.  
Ultrasound examination 
In the TTA study (Paper IV), rats from the following groups of the study population 
were randomly selected for ultrasound examination: control group 1 (n = 7), DSS 
group 2 (n = 7), TTA + DSS group 3 (n = 7). The rats were anesthetized by inhalation 
of 2 % Isoflurane. The distal colon wall thickness was then measured using a Vivid 7 
ultrasound machine (GE Vingmed Ultrasound A/S, Horten, Norway) with 14 MHz 
linear ultrasound probe (12L, GE Health- care, Milwaukee, USA). The urinary bladder 
was used as an acoustic window, and also provided a standardized level of distal colon 
measurements. The mean of three values per animal was reported. The investigator 
was unaware of which group the rats belonged to. The examination cannot be 
considered blinded however, as the health condition for some of the colitic rats were 
evidently poor. In the DSS group 2, the measurements from one animal were not 
adequate and results were thus omitted.   
Prostaglandin analysis 
Preparations 
All eicosanoids were purchased from CalBiochem, La Jolla, CA, USA. Stock solutions 
of deuterated standards (CalBiochem) were kept in 50/50 EtOH/H2O (Kemetyl Norge 
AS, Fredrikstad, Norway) at -80°C and diluted in ultrapure distilled water immediately 
before sample preparation to avoid any oxidation. Frozen colon tissue samples (12–35 
mg) were added to a solution of ice-cold 0.1% butylated hydroxytoluene (BHT) 
(Sigma-Aldrich, St. Louis, MO, USA) in ultrapure distilled water (1:100 (w/v)) and 
homogenized by a Virtishear homogenizer at 25,000 rpm for 2 x 30 s. Then 50 µL 
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internal standard solution (PGE2d4 150 pg/µL; PGD2d4 250 pg/µL) was added to 
1200 µL homogenisate. The samples were sonicated for 60 s and centrifuged at 12,000 
rpm for 5 min at 5°C. Later, 1,125 µL supernatant were evaporated to dryness under a 
stream of nitrogen at room temperature. Then the samples were reconstituted in 50 µL 
of 50/50 EtOH/H2O (v/v) before LC/MS/MS analysis. 
LC/MS/MS 
The LC-system was an Agilent (Waldbronn, Germany) 1200 Series with binary pump, 
variable volume injector, and a thermostated autosampler. HPLC separation was 
performed using a gradient solvent mixture at 20°C. Mobile phase A was made of 10 
mM ammonium acetate (Merck, Darmstadt, Germany) in water with pH adjusted to 
8.5 with ammonia solution 25% (Merck) Mobile phase B was methanol (Fisher 
Scientific, Leicestershire, UK). The gradients were B 0.1 min 0-40%, B 18 min 40–
60%, B 1 min 60–100%, B 6 min 100%, B 0.1 min 100-0% and B 5 min 0%. Flow 
was 0.25 mL/min and a Phenomenex Luna Phenyl-Hexyl column (3 µm, 150 x 2 mm) 
was used. A 10 mL sample was injected. The mass spectrometer used was an Agilent 
6410 Triple Quad LC/MS (USA) equipped with an electrospray source. Source 
parameters: gas temp 350°C, gas flow 12 L/min, nebulizer 40 psi, capillary 4000 V. 
Multiple reaction monitoring (MRM) for data acquisition and negative ion detection 
was used. MassHunter software (Agilent) was used for HPLC system control, data 
acquisition, and data processing. The prostaglandins analyzed were expressed as µg/kg 
(wet tissue) in Paper II and as pg/mg (wet tissue) in Paper III. 
Fatty acid analysis of colon total phospholipids 
In order to avoid contamination from surrounding neutral lipids, extraction of total 
colon lipids was followed by TLC separation of lipid fractions. We then used the PL 
fraction only for colon FA analyses. 
Extraction of colon lipids 
Colon tissue samples of 10-25 mg were homogenized in 2.5 ml of methanol for 30 sec 
(Ultra-Turrax T25 basic homogenizer, IKA-Werke, at speed 11000 rpm/min) in a glass 
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test-tube with a teflon-lined seal cap. Then 1.25 ml of chloroform was added and 
extracted overnight at 4°C with an occasional shaking. After centrifugation, the 
supernatant was transferred into a new glass test-tube and the sediment was re-
extracted for 1 hour in solvents as above. To the collected supernatants, chloroform 
and water was added to the ratio methanol:chloroform:water (1:1:0.9) (79). After 
phase separation, lower chloroform phase was used for lipid analysis. 
TLC separation of lipid fractions 
Aliquots of chloroform extracts were applied on TLC plates 10 x 20 cm Silica gel 60 
(layer thickness 250 µm, particle size of 10 - 12 µm) (Merck, Germany) in a line 0.5 x 
2 cm. The plates were developed in a tightly closed depeloping chamber in 
hexane/diethyl ether (50:50, v/v). The spots were visualized by ultraviolet-light after 
spraying with Rhodamine 6G (0.01% in methanol, w/v) and identified by means of co-
eluting lipid standars (Sigma-Aldrich, USA). The silica gel with the spots of total 
phospholipids were scraped off into glass test-tubes with teflon-lined seal caps (80). 
Transesterification of total phospholipids 
To the total phospoholipids scraped off with silica gel 1.0 ml of 2% H2SO4 in methanol 
(v/v) and 1.0 ml toluene containing appropriate amount of C21:0 was added and 
heated for 2 hr at 90
o
C (69). At the end of the heating, the samples were cooled off to 
room temperature, 0.3 ml water and 300 µl 1.5 M K2CO3 in water was added. After 
centrifuging, about 200 µl of the toluene upper layer containing fatty acid methyl 
esters was transferred into autosampler vials and stored at -20
0
C before analyzed by 
GC. GC conditions and method of fatty acids identification were as described earlier 
in fatty acid analysis of total lipids. 
Oxidative stress markers 
Glutamic semialdehyde (GSA), carboxymethyl-lysine (CML), carboxyethyl-lysine 
(CEL), aminoadipic semialdehyde (AASA) and malondialdehyde-lysine (MDAL)  
concentrations in samples from the proximal and distal colon were homogenated in   
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0,5 mg protein and measured by gas chromatography/mass spectrometry (GC/MS) as 
previously described (81).  
Samples were delipidated using chloroform/methanol (2:1, v/v), and proteins 
were precipitated by adding 10% trichloroacetic acid (final concentration) and 
subsequent centrifugation. Protein samples were reduced overnight with 500 mM 
NaBH4 (final concentration) in 0.2 M borate buffer, pH 9.2, containing 1 drop of 
hexanol as an anti-foam reagent. Proteins were then reprecipitated by adding 1 ml of 
20% trichloroacetic acid and subsequent centrifugation. The following isotopically 
labeled internal standards were then added: [
2
H8]lysine (d8-Lys, CDN Isotopes); 
[
2
H4]CML (d4-CML), [
2
H4]CEL (d4-CEL), and [
2
H8]MDAL (d8-MDAL) prepared as 
described (82, 83) and [
2
H5]5- hydroxy-2-aminovaleric acid (for GSA) and [
2
H4]6-
hydroxy- 2-aminocaproic acid (for AASA) prepared as described (40, 84).   
   The samples were hydrolyzed at 155 °C for 30 min in 1 ml of 6 HCl, and then 
dried in vacuo. The N,O-trifluoroacetyl methyl ester derivatives of the protein 
hydrolysate were prepared as previously described (40).    
GC/MS analyses were carried out on a Hewlett-Packard model 6890 gas 
chromatograph equipped with a 30-m HP-5MS capillary column (30 m × 0.25 mm × 
0.25 µm) coupled to a Hewlett-Packard model 5973A mass selective detector (Agilent, 
Barcelona, Spain). The injection port was maintained at 275 °C; the temperature 
program was 5 min at 110 °C, then 2 °C/min to 150 °C, then 5 °C/min to 240 °C, then 
25 °C/min to 300 °C, and finally hold at 300 °C for 5 min. Quantitation was performed 
by external standardization using standard curves constructed from mixtures of 
deuterated and non-deuterated standards. Analytes were detected by selected ion-
monitoring GC/MS (SIM-GC/MS). The ions used were: lysine and d8-lysine, m/z 180 
and 187, respectively; 5-hydroxy-2-aminovaleric acid and d5–5-hydroxy-2-
aminovaleric acid (stable derivatives of GSA), m/z 280 and 285, respectively; CML 
and d4-CML, m/z 392 and 396, respectively; CEL and d4-CEL, m/z 379 and 383, 
respectively; 6-hydroxy-2-aminocaproic acid and d4-6-hydroxy-2-aminocaproic acid 
(stable derivatives of AASA), m/z 294 and 298, respectively; and MDAL and d8-
MDAL, m/z 474 and 482, respectively. The amounts of products were expressed as 
the ratio of micromole per mole Lys of GSA, CML, CEL, AASA and MDAL.  
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Gene expression   
Distal colon samples were frozen in liquid nitrogen immediately after dissection and 
stored at −80°C. Total cellular RNA was purified from 20 mg frozen tissue using a 
TissueLyser II with 5-mm stainless steel beads, and the RNeasy Fibrous Tissue Mini 
Kit (Qiagen, Valencia, CA, USA). RNA was quantitated spectrophotometrically 
(NanoDrop 1000; NanoDrop Technologies, Boston, MA), and the quality was 
evaluated by capillary electrophoresis (Agilent 2100 Bioanalyzer; Agilent 
Technologies, Palo Alto, CA). For each sample, 400 ng total RNA was reversely 
transcribed in 20-µl reactions using Applied Biosystem's High Capacity cDNA 
Reverse Transcription Kit with RNase inhibitor according to the manufacturer's 
description. Real-time polymerase chain reaction was performed with custom-made 
384-well microfluidic plates (Taq-Man Low Density Arrays (TLDA), Applied 
Biosystems, Foster City, CA) on the following genes: Ppargc-1a, Rn00580241; 
Pparg, Rn00440945; Nos2, Rn00561646_m1; Il-6, Rn 00561420; Il-1b, 
Rn00580432_m1; KC-GRO (Cxcl1), Rn00578225_m1; Ptgs2 (Cox2), 
Rn01483828_m1; Ptges, Rn00572047_m1; Ptgds, Rn00564605_m1; Tlr4, 
Rn00569848_m1; sirtuin 1 (Sirt1), Rn 01428093_m1; Sirt4, Rn01481485_m1. 
All probes and primers were obtained from Applied Biosystems. Two different control 
genes were included: 18s (Kit-FAM-TAMRA (Reference RT-CKFT-18s) from 
Eurogentec, Belgium, and Rplp0 (Rn00821065_g1) from Applied Biosystems. 
To normalize the absolute quantification according to the reference genes, a 
second set of PCR reactions was performed for all experimental samples, and the 
relative abundance values were calculated for the reference genes as well as for the 
target genes using standard curves derived from Universal Rat Reference RNA, 
(Agilent Technologies inc., Santa Clara, CA, USA). The software NormFinder was 
used to evaluate the reference genes, and the relative abundance value of each gene in 
each sample was normalized against the value of the two reference genes (18s and 
Rplp0) (in Paper II) or the most stable reference gene, Rplp0 (in Papers III and IV) 
(85).  
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3.3 Statistical methods  
Distribution of data was examined by Shapiro–Wilks test. For normally distributed 
data parametric statistics were applied and mean with 95% confidence intervals 
reported. For differences between two or more groups, Student´s t-test for paired 
(Paper I) and unpaired (Papers III –IV) samples, or One-way analysis of variance 
(ANOVA) were used, respectively.  
For non-normally distributed data, non-parametric statistics were used and 
median values with ranges reported. For differences between two or more groups, 
Wilcoxon matched pairs signed-rank test (Paper I), Mann-Whitney rank test (Papers 
III and IV) or Kruskal-Wallis one-way analysis of variance test (Paper II) were 
performed, respectively. 
Correlation coeffecients were calculated using Spearman rank correlation test  
(Paper I). Post-hoc tests were performed by Mann–Whitney rank test (Paper II). A p-
value < 0.05 was considered statistically significant. Corrections for multiple testing 
were performed in Papers II and III except for the fatty acid and gene expression 
analyses.  
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4. Summary of results 
 
Paper I 
The twelve patients that completed the study had a significant decrease of SCCAI after 
salmon intake (p=0.007), a close to significant drop in CRP (p=0.07) and the 
concentrations of AA, “C20:4n-6” in rectum tissue specimens, correlated with 
endoscopic and histopathological score at visit 2. EPA, DHA, total n-3 levels as well 
as AIFAI were all elevated in both plasma and rectum. However, fecal calprotectin 
levels and histological score were not altered after salmon diet. 
Paper II 
There was a significant reduction of HCS after fish peptides diet as compared with fish 
oil (p=0.03). DAI also decreased, not reaching statistical significance (p=0.07). 
KC/GRO protein levels in colon was lower after fish peptide intake (p<0.05). Fish oil 
increased the DAI as compared with DSS alone, and elevated PGE3 levels. In addition, 
the combined fish oil + fish peptides diet increased the PGE3 levels even more than 
fish oil alone. A number of beneficial changes occurred after fish peptides diet vs. 
DSS alone, not reaching statistical significance. 
Paper III 
We found a retained colon length, and reduced levels of selected protein oxidant 
variables in rats following krill oil diet, as compared with rats fed standard diet  + 
DSS. The EPA, DHA, n-3/n-6 ratio and the AIFAI were beneficially 
changed/increased. Moreover, a consistent tendency of improved HCS, cytokine and 
PGE3 levels, as well as mRNA levels of PPAR-γ and Ppargc-1α occurred, although not 
significantly.  
We also detected significant differences between the control and the control + 
DSS groups in variables like weight gain, DAI, HCS, colon length, cytokines at both 
protein and mRNA levels, in accordance with a colitic state after DSS exposure. 
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Paper IV 
Following the TTA diet, cytokines were reduced at protein level for TNF-α, and at 
mRNA levels for IL-1β and IL-6. The levels of all oxidative markers except AASA 
decreased versus DSS alone. DAI and HCS were not significantly altered. PPAR-γ 
expression was significantly upregulated after TTA intake. Transabdominal ultrasound 
showed a significant increased distal colonic wall thickness in DSS exposed rats 
versus control rats. In addition, TTA + DSS diet reduced colonic wall thickness as 
compared with DSS alone.  
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5. Discussion 
The main hypothesis that nutritional products from mostly marine sources have anti-
inflammatory effects in UC patients or in an experimental animal IBD model was 
tested in one human and three animal studies.  
We found that a regular salmon intake for eight weeks reduced the SCCAI in 
patients with UC. We then tested dietary salmon components in experimental rat 
colitis, and found that a fish peptide diet attenuated DSS colitis as compared with fish 
oil diet. Furthermore, a combined fish oil and fish peptides diet could beneficially 
influence prostaglandin metabolism. We revealed that dietary krill oil may diminish 
DSS induced rodent colitis and reduce protein oxidative damage. We then 
demonstrated that a modified fatty acid (TTA) seems to have have anti-inflammatory 
and anti-oxidative effects in DSS induced rat colitis. Finally, we found that high 
frequency transabdominal ultrasound is able to distinguish between normal and 
inflamed colon in the DSS model, as seen by increased wall thickness. 
5.1 Evaluation of main findings 
Paper I. The hypothesis tested in this study was that salmon fillets might have an anti-
inflammatory effect in patients with UC. As fish fillets contains substances like fish 
proteins and peptides in addition to fish oil, we considered this intervention as 
different from a pure fish oil supplemented diet only. A number of studies in human 
IBD have been conducted regarding n-3 PUFA supplementation, with inconsistent 
results, for selected studies, see Table 3. Systematic reviews and metaanalyses (92-95) 
have not found clear evidence for a beneficial effect. This may be attributed to 
differences in study designs, different n-3 formulas and doses, as well as different 
types of placebo substances used (95).   
 Fish /salmon consumption provide other substances than n-3 PUFAs, such as 
bioactive peptides (43). We are not aware of other IBD studies involving salmon diet,  
except for a study in coronary heart disease where intake of salmon diet resulted in 
lower vascular inflammatory activity (96).  
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 Our study diet probably contained sufficient daily amounts (at least 3.4 grams) 
of n-3 PUFAs to expect anti-inflammatory effects, as amounts between 2.7-5.6 grams 
have proved effective in previous trials (97). 
At inclusion, we regarded a SCCAI of ≥ 4 as indicative of active colitis. 
However, during the wash-out period we observed a reduction in SCCAI from a 
median of 5 (inclusion) to 3 (start of intervention). Following salmon intake, the    
SCCAI was further reduced to 1.5. The drop in SCCAI from 5 to 3 during the wash-
out period could possibly be attributed to a “regression towards the mean” effect, 
and/or a placebo effect.  
SCCAI levels to determine remission or disease activity improvement have 
been defined differently in previous studies (98, 99). One report, based on patient 
defined cut-off levels, suggested a SCCAI of < 2,5 as remission and a drop of  > 1,5 as 
improvement (99). It could thus be discussed whether the SCCAI reduction observed 
in our study of 1.5 is clinically significant. 
The AIFAI is not a validated index, but the increase that occurred after salmon 
intake may reflect a beneficial change of the fatty acid profile, and has been associated 
with decreased levels of pro-inflammatory eicosanoids like PGE2 (36). The tendency 
to lower CRP following salmon diet supports such anti-inflammatory effect. 
High levels of polyunsaturated marine fatty acids predisposes for lipid 
peroxidation reactions (100), but MDA, a marker of lipid oxidation, rather tended to 
decrease in our study.   
The background daily intake of n-3 PUFAs of 2.5 grams as indicated by the 
FFQ analyses, could have influenced the results. Despite a four-week wash out period, 
a carry over effect could possibly have “saturated” the tissues to some extent.  Even 
ten weeks have been claimed to be a too short interval to allow complete wash out 
(101).  
A limited anti-inflammatory effect could be due to different genetic variants of 
G-protein coupled receptor 120 (GPR 120) that mediate n-3 fatty acid anti-
inflammatory effects. In GPR 120 knock-out mice, n-3 PUFAs were not effective 
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(102). Thus, the expression of GPCR may determine responders and non-responders 
towards n-3 mediated effects (102). 
The small study population and lack of controls complicate firm conclusions to 
be drawn from this pilot study.     
 
Paper II. In this study we found that a diet containing 3.5 % salmon derived fish 
peptides reduced DSS induced inflammation compared with fish oil diet, as assessed 
by HCS. Also, KC/GRO protein levels were significantly lowered. DAI was reduced 
although not reaching statistical significance. Several other variables had a “beneficial 
shift” without being statistical significant.  
Fish is an important dietary source of bioactive peptides that may have diverse 
biological effects (43). Small peptides may be absorbed unaltered into the circulation 
to exert physiological effects. Most bioactive peptides are not absorbed and are 
believed to act directly in the gut via receptors (42). Other bioactive peptides are 
encrypted in proteins and must be released by digestive or microbial proteolytic 
enzymes to gain biological activity (42). 
Some evidence point to reparative or anti-oxidant properties from fish derived 
hydrosylates (44-46). The effect of fish peptides in IBD models has not been much   
investigated. One brief report suggests symptom reduction and lowered intestinal 
permeability following intake of fish hydrolysate (47). We used fish peptides of 
optimal small sizes and weights regarding bioactivity and lipid lowering (103).  
The results suggest a beneficial effect of fish peptides, most evident when 
compared with fish oil, and not with DSS alone. Several previous studies in rodent 
IBD models have shown attenuated intestinal inflammation following fish oil 
supplementation or combinations with other substances, for selected studies see Table 
4.  
These results contrast our study, where fish oil diet did not have beneficial 
effect on histology or cytokine measures. In fact, DAI increase suggested an 
unfavourable effect, possibly caused by increased lipid peroxidation, as no vitamin E 
had been added to the fish oil diets. However, we did not disclose increased protein 
oxidative damage.  
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Increased inflammation in IBD models after fish oil supplementation has been 
previously reported (108) and it has been speculated whether reduced T reg function 
could be responsible (109). Also, there could be an “upper tolerable limit” for n-3  
PUFAs /DHA in IBD. A combination of soybean oil and fish oil appeared more 
beneficial than pure fish oil supplementation in rat experimental colitis (107). 
However, no current data supports that EPA and DHA exert unfavourable 
immunosuppressive effects leading to higher risk of infections (110). 
   The salmon diet used in Paper I reduced SCCAI. Salmon contains both fish 
oil and fish peptides. In the DSS model, fish oil alone increased DAI, but the 
combined fish oil and fish peptides diet appeared to dampen the negative effect from 
fish oil alone. The reason for this is unclear, but could reflect an anti-oxidant effect by 
fish peptides (43). Salmon also contains the natural anti-oxidant astaxanthin (111).  In 
addition, a synergy effect on prostaglandin synthesis, favouring production of less 
inflammatory eicosanoids such as PGE3 may contribute.   
 
Paper III. In this study we investigated the anti-inflammatory and anti-oxidant effects 
of krill oil in the DSS model. This marine oil has large amounts of its EPA and DHA 
bound to phospholipids in contrast to fish oil, where these PUFAs are largely bound to 
triglycerides (34). Krill oil contains the carotenoid anti-oxidant astaxanthin (112). In 
contrast, the fish oil diets were without vitamin E, an anti-oxidant often used in fish oil 
products to protect against lipid peroxidation. 
We found that rats fed krill oil diet had preserved colon length. Colon 
shortening is typically experienced after DSS induced colitis, and may result from 
mucosal oedema, increased vagal tone, or muscular contraction (75).   
There were no other significant changes in disease activity variables. A number 
of consistent changes, although each of them not being statistically significant, was 
evident for DAI, HCS and cytokines at both protein- and mRNA levels. Together with 
the increased PGE3 levels, these results suggest a protective effect of krill oil in the 
DSS-induced colitis. This is in accordance with previous animal IBD studies using fish 
oil derived n-3 PUFA supplementation (see Table 4), whereas our study is the first 
trial of krill oil in an IBD model.  
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The fat content of krill - 1,5% of total weight - is lower than in fat fish such as 
salmon (5.9%), but the PUFA content and EPA + DHA amount in krill is higher, 
29.8% vs 18.3% (34). Krill oil therefore seems to be an adequate source of marine 
fatty acids. This was also confirmed by fatty acid analyses, showing increased levels 
of EPA, DHA, DPA, n-3/n-6 ratio as well as AIFAI in rat colon tissue after krill oil 
intake.  
EPA and DHA may work through several mechanisms to dampen 
inflammation. A classical hypothesis is that EPA competes with AA as substrate for 
COX and LOX enzymes resulting in production of less inflammatory eicosanoids, 
such as PGE3, found to be increased in our study (32). Other possible mechanisms are 
changes in lipid rafts that constitute important parts of receptor complexes and 
signalling molecules in membranes of T cells and dendritic cells. Increased amounts of 
EPA and DHA may alter the lipid organization of such rafts, and downregulate 
inflammatory responses (35). Also, resolvins and neuroprotectins are molecules with 
anti-inflammatory properties, originating from EPA and DHA (33, 35). Future studies 
of anti-inflammatory effects from n-3 fatty acids should investigate the effects of these 
substances. Finally, activation of nuclear receptors and modulation of gene 
transcription may be important effects from EPA and DHA: PPAR-γ is higly 
expressed in the colon, and may be activated upon ligand binding by EPA or DHA. 
PPAR-γ activation inhibits NFκB, an important pro-inflammatory transcription factor. 
Consequently, the production of pro-inflammatory substances such as IL-1β, IL-6, 
TNF-α, COX-2, iNOS and chemokines is downregulated. (57, 113). In another study, 
PPAR-γ expression was decreased in rectal mucosa in UC patients with active disease 
(114). In accordance with this, we found that the expression of PPAR-γ, as well as 
PPARGC-1α, a coactivator related to PPAR-γ, were reduced in the DSS group as 
compared with controls.  
It is not clarified if krill oil´s chemical structure improves its bioavailability. 
Similar plasma levels of EPA and DHA were observed after a smaller krill oil dose 
(62.8%) as compared with fish oil dose (115).   
Oxidative stress was assessed by markers that have scarcely been tested in IBD 
models earlier. The protein carbonyl compunds CEL, CML and GSA were reduced 
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following krill oil diet, indicating reduced protein oxidative damage and less 
inflammation. Increased oxidative stress in form of elevated levels of ROS occurs in 
IBD, and may also be a pathophysiological factor (116). Protein carbonyl levels in 
mucosal biopsies from CD and UC patients were increased in a previous study (117). 
In IBD patients, pentosidine, another AGE product was increased in urine and 
intestinal tissue and reflected disease activity (63). This suggests that AGE products 
may influence inflammation in IBD, and CEL and CML measurements were thus 
relevant in our rat model of IBD.  
 
Paper IV. In our fourth study, we explored the anti-inflammatory and anti-oxidant 
effects of the modified fatty acid TTA in the DSS colitis rat model.   
Non-invasive, transabdominal ultrasound examination with a relatively high 
frequency (14 MHz) was able to differentiate between inflamed and normal rat colon 
based on measurement of wall thickness. In this exploratory study, we also observed a 
difference between rats fed TTA versus rats fed DSS alone. Although this method is 
not validated, another pilot study also showed that ultrasound may differentiate 
between colitic and non-colitic rats following DSS as well as TNBS exposure (118). 
Biomicroscope ultrasound imaging in rat colitis on ex vivo samples using a 50 MHz 
scanner has shown promising results, but used a more cumbersome set up (119). 
Future ultra-high frequency transabdominal studies may improve resolution and 
accuracy of this method.   
We found that TTA reduced TNF-α protein levels, and IL-1β and IL-6 mRNA 
levels, indicating an anti-inflammatory effect.  
We also observed a reduction in protein oxidative damage markers as seen by 
reduced GSA, CEL, CML and MDAL, supporting the anti-oxidative potential from 
TTA. These markers were not significantly elevated in the DSS vs control group, but 
showed a consistent tendency to increased levels. Their role in human IBD and IBD 
animal models should be further investigated in future studies. 
As in the krill study, Sirt1 gene expression was elevated following intervention, 
although not significantly. In addition, Sirt4 mRNA levels were higher following TTA 
intake. Both Sirt1 and Sirt4 expression levels decreased significantly in DSS vs 
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controls, suggesting that elevated levels mediate beneficial effects. In fact, SIRT1 may 
act as an inhibitor of NFκB activity, and decreased levels of Sirt1 gene expression 
were associated with increased NFκB activation and colitis in mice (59). 
We observed an increase in Pparg, but not of Ppargc1a mRNA levels, 
following TTA diet. PPAR-γ inhibits NFκB activation, which in turn may 
downregulate the production of pro-inflammatory cytokines and chemokines (53). In 
accordance with this, a consistent reduction of all measured cytokines occurred, at 
protein and/or at mRNA level, although not all significantly. The role of PPARGC1A 
is less understood in inflammatory conditions. Increased expression of both Pparg and 
Ppargc1a were associated with attenuated colitis and later onset of DSS colitis in pigs 
that were fed conjugated linoleic acid (120).  
5.2 Evaluation of methods 
Ulcerative colitis study 
The original design of this study included 25 patients with active UC that received 
salmon diet and 25 patients with active UC, serving as controls. This number was not 
achievable for the following reasons: 
1) -  Recruitment of patients with active colitis that could manage 12 weeks study 
period without changing medication was more difficult than expected. 
Moderate to severly affected patients were not considered suitable as they 
needed treatment with corticosteroids.  
2) -  The salmon fillets were of limited durability, allowing an inclusion period of 
6 months only. It was decided not to produce another batch of salmon for this 
study to prolong inclusion. As a result, the patient population could not be 
increased. 
3) -  Verification of active colitis was based on an objective marker – f-
calprotectin, thus ruling out 5 patients with too low levels. 
4) -  Drop out; Patients had problems keeping to the treatment protocol for the 
eight weeks with high salmon intake. 
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The most important factors that could have improved the study would have 
been a prolonged inclusion period, which would probably have increased the sample 
size and provided a control group. This would have strenghtened the statistical power 
of the analyses. 
Endoscopical evaluation: A limited sigmoidoscopy is better tolerated by the 
patients than coloscopy, and was considered adequate because rectal inflammation was 
expected in all cases of colitis. A complete colon examination by coloskopy could 
have revealed inflammation in other colon segments as well, and the complete disease 
distribution was thus not assessed.  
Animal studies  
The DSS colitis model  
This chemically induced colitis model is a widely used UC model, with a predictable 
onset and consistent location of colitis. Acute DSS colitis is shown to increase the 
gene expression of IL-6, CXCL1 (also called KC in rodents or GRO-α in humans) and 
Prostaglandin endoperoxide synthase 2 (Ptgs2)/cox2, as well as giving rise to 
increased levels of IL-1β, TNF-α and KC in colon specimens. This is analogue to 
human IBD, strengthening the relevance of these variables used in our experiments 
(48, 121).   
 We used 5% DSS with a MW of 44 kDa, known to induce a more severe colitis 
in the middle and distal colon, as opposed to induction with 5 kDa DSS or 2-3% DSS, 
which result in a more patchy and mild inflammation (48). If the colitis was less 
pronounced, weaker effects from the diets could have been easier to reveal.  
This acute injury model has limitations. Although with several similarities, it is 
clearly different from the human IBD, being an exogenously triggered inflammation, 
opposed to the more complex human disease. A genetically modified UC model, such 
as the IL-2 knockout or T cell receptor mutant model, would possibly have been a 
more optimal model to investigate (122). 
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Study design  
To minimize the total number of animals, 70 rats were included in a single large 
experiment, providing seven groups of 10 rats in each: (a) Control, (b) control + DSS , 
and five dietary intervention groups : (c) fish oil, (d) fish peptides, (e) combined fish 
oil and fish peptides, (f) krill oil and (g) TTA that were exposed to DSS the last week 
(Figure 6). If three separate experiments had been performed, 40 more animals would 
have been needed for separate control and control+DSS groups in each trial.  
On the other hand, for each dietary group with DSS colitis, an additional control 
group without DSS could have been added. In the krill oil study, relevant groups 
would then be: 1) control, 2) control + DSS, 3) krill oil + DSS, and 4) krill oil (without 
DSS). Although the design was not optimal, we still think the current design have 
provided interesting findings.  
Diets were administered during the four weeks in order to give the dietary 
components an opportunity to reach a steady state of maximal concentration in tissues. 
The DSS exposure was therefore withheld until the last week of the study. Our study 
design can therefore not differentiate between prophylactic and therapeutic effects. 
In Paper III we report findings in the DSS versus the control group. The 
purpose of these controls was to have a reference point of normality, without colitis. 
DAI, HCS, colon length, as well as cytokines at protein an mRNA levels were 
increased in the DSS exposed controls versus control animals. This supports that  
colitis was induced, and strenghtens the relevance of the selected variables in this 
inflammatory model.    
The protein oxidative markers have not been widely used in IBD models earlier, 
and we were unable to reveal significant differences between control rats and the DSS 
group, even though the levels in the DSS group were consistently higher for all three 
oxidative stress markers. We suspect that a higher number of animals analysed may 
have been clarifying. Unfortunately, technical problems during GC/MS analysis 
prohibited this, only permitting four rats to be analysed in each group. 
DAI was only measured the last day of the experiment, because the animals had 
to be single caged and our laboratory resources were limited. 
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Cytokine analyses 
We used full wall samples from rat colon in the cytokine analyses. In previous studies, 
small intestinal and also colon mucosal specimens have been mechanically scraped off 
in order to analyse cytokine levels in mice and rat IBD models (123, 124). As it 
proved difficult to perform this in rat colon during preliminary tests, it was decided to 
use full wall sections of colon. An excisting method for colon tissue homogenization 
in mice provided from Meso Scale Discovery (MSD, Gaithersburg, MD), was 
modified by us for use on rat colons. The method was optimized regarding colon 
sample weights, homogenisate preparations and phosphatase inhibitor concentrations.  
Ultrasound 
This method is non-invasive and still provides adequate measurements in skilled 
hands. One limitation is that the quality of the examination is largely investigator 
dependent. The small dimensions of the rat colon wall requires a very high ultrasound 
frequency. We suspect that the frequency of 14 MHz is probably not optimal in rats 
and should have been higher. This is considered another weakness of the examination.  
LC/MS/MS   
This method of combining HPLC with tandem MS for analysis of prostanoids allows 
highly sensitive, selective and simultaneous measurements, without the need of 
derivatization. A general limitation of this method is “ion suppression”, considered as 
a matrix effect that may reduce detection, precision and accuracy of the LC/MS/MS 
method. Another limitation was the use of PGE2 as internal standard for PGE3 
measurements, as an PGE3 internal standard is not available.  
GC/MS  
This method used for analyzing markers of protein oxidation is very selective, with 
high ability to separate relevant substances, and sensitive, being able to detect small 
amounts of the relevant substance. The sample work-up is demanding with the need 
for several steps, which may be regarded as a limitation of the method. Another 
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limitation was, during the DSS study, technical problems with the GC limited the 
number of animals anlysed to four in each group. 
Fatty acid analyses  
Fatty acids from the tissues were analyzed by gas chromatography (GC) after 
preparation of fatty acid methyl esters, which are more volatile and less polar than the 
original lipids or potentially free fatty acids. That makes the GC analysis possible at 
lower temperatures which protect especially unsaturated fatty acids against 
degradation, peaks are symmetric and quantitation is more exact.  
When total fatty acids were measured, a direct trans-esterification of lipids with 
whole tissue permitted a rapid analysis, with less loss of material.  
In the DSS rat model, we isolated the phospholipid fraction for fatty acid 
analyses. This should avoid influences from surrounding fat tissue on the results.  
Fatty acid analyses from colon specimens were only performed in the krill oil 
study due to limited resources. It is considered a limitation of Paper II not to report the 
colon tissue fatty acid profile, especially in the groups receiving fish oil diets.   
Another weakness of the DSS experiment using this method is that direct 
structural analysis of lipids and to measure a position of individual fatty acids in the 
lipid molecules is not possible. Finally, some of the phospholipids may be lost 
quantitatively when scraping off the phospholipids from the thin layer chromatography 
plate.  
Genetic analyses 
The method has been validated and all components are commercially available. We 
used only one distal colon tissue specimen from each rat for gene expression analysis. 
As the inflammation grade may vary in different colon sections, the use of several 
specimens could have improved the method. In addition, the low-grade expression of 
some cytokines resulted in large variance of the data, also regarded as a limitation of 
this method. 
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5.3 Statistics 
Ulcerative colitis study  
Power estimation: 25 x 2 patients in the intervention and control groups would detect a 
difference of 20% or more with a power of 80% at a significance level of 0.05. 
However, this number of subjects was not possible to achieve.  
Animal studies 
Power estimation: Based on previous findings where fish oil supplemented diet clearly 
reduced pro-inflammatory markers we estimated that 10 animals per group would be 
sufficient to detect a 50% difference with a power of 80% at a significance level of 
0.05.  
However, many variables in our studies did not reach these differences between 
groups, resulting in a number of non-significant findings. In addition, the DSS control 
group displayed large data variation in several variables.  
In Papers II and IV the data were pairwise analysed in order to focus on the rats 
with colitis.  
Paper II: (a) Control vs. DSS and  (b) DSS vs. Krill oil 
Paper IV: (a) Control vs. DSS and (b) DSS vs. TTA 
In Paper III, we preselected a limited number of paired analyses due to multiple 
groups, a limited number of animals per group and the number of analyses: 
1) DSS vs. Fish oil 
2) DSS vs. Fish peptides 
3) Fish oil vs. Fish peptides  
4) Fish oil vs. Fish oil + fish peptides 
In this explorative setting, we wished to avoid a massive correction for multiple 
testing, discarding all significant differences between the DSS exposed groups.  
Descriptives 
Limited data regarding feed and DSS intake were due to keeping five animals per cage 
and difficulties in obtaining individual rat data.   
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5.4 Summary 
In this study we found that regular high intake of Atlantic salmon reduced the SCCAI 
in patients with active colitis, improved the fatty acid profile in plasma and rectal 
biopsies, but this could not be supported by other disease variables. We thereafter 
explored the anti-inflammatory and anti-oxidant effects of different salmon 
components, (fish oil, fish peptides or a combined diet), in a colitis model in rats. In 
these studies we demonstrated that fish peptides may attenuate DSS colitis as 
compared with fish oil, but had no significant effect when compared with rats fed 
DSS. The mechanisms behind a beneficial effect from pure fish peptides diet are 
unclear, but the combined fish oil+fish peptides diet enhanced production of the anti-
inflammatory PGE3 more than expected from the fish oil component alone. We 
speculate that the latter effect may be caused by an increased activity from enzymes 
involved in eicosanoid synthesis.  
We conducted the first dietary krill oil intervention study on experimental UC 
and demonstrated that it may dampen DSS colitis assessed as persistence of colon 
length and reduced protein oxidation in rats. Although not all measured variables 
improved significantly, there was a consistent change of most variables towards an 
anti-inflammatory pattern. However, further studies are needed to confirm this finding. 
Results from dietary supplements of TTA supported earlier findings of anti-
oxidant effects and anti-inflammatory potential by reducing cytokine levels at mRNA 
or protein levels. In addition, analysis of a subgroup of rats by a novel ultrasound 
examination method detected a clear difference in abdominal wall thickness between 
normal rats and DSS exposed rats. Furthermore, we were able to demonstrate a 
decreased wall thickness in TTA fed rats, in accordance with the cytokine and protein 
oxidant findings. 
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6. Future perspectives 
In future animal studies, the effect of marine nutritional products should be tested in 
chronic, mild intestinal inflammation. Genetic IBD models may be preferable in this 
respect. Fish peptides may enhance the effect of n-3 PUFAs and should be further 
explored together with krill oil. Novel anti-inflammatory products from EPA and 
DHA metabolism such as resolvins and neuroprotectins should be further assessed in 
future studies, and supplemented in therapeutic trials in IBD models. 
 Krill oil should be further tested in IBD patients, possibly in combination with  
medical treatment, and in both patients with active and inactive IBD. However, as the 
anti-inflammatory potential from these marine products appears limited, future 
research should aim to select responders on dietary therapy. Determining GPR 120 
receptor status before administering dietary n-3 PUFA may be an example of this.   
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